AIM Vaccine Co., Ltd. engages in biological vaccine technology development, technology transfer, and technical services. Its products include Recombinant hepatitis B vaccine, Freeze-dried Human Rabies vaccine, Inactivated Hepatitis A vaccine, Live Attenuated Parotitis vaccine, Inactivated HFRS vaccine, and ACYW135 Meningococcus Polysaccharide vaccine. The company was founded on November 9, 2011 and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company